Actinogen Medical — XanaMIA passes interim analysis and marches on
Actinogen Medical’s interim analysis of its XanaMIA Phase IIb/III study of lead candidate Xanamem (emestedastat) in patients with mild-to-moderate...
130 Views
Actinogen Medical — XanaMIA passes interim analysis, marches on
Actinogen Medical’s interim analysis of its XanaMIA Phase IIb/III study of lead candidate Xanamem (emestedastat) in patients with mild-to-moderate...
121 Views
Actinogen Medical — XanaMIA passes first safety milestone
Actinogen Medical reported that the independent Data Monitoring Committee (DMC) of the company’s pivotal Phase IIb/III XanaMIA study in patients...
204 Views
Actinogen Medical — XanaMIA recruitment exceeds expectations
Actinogen Medical reported that, due to recent accelerations in screening and enrolment for its Phase IIb/III XanaMIA study of lead candidate...
248 Views
Actinogen Medical — An eventful period ahead for Xanamem
Actinogen’s FY25 results highlighted the company’s progress in advancing its lead candidate, Xanamem, through its pivotal XanaMIA Phase IIb/III...
297 Views